Meningococcal (groups a, c, w-135 and y) oligosaccharide crm197 conjugate vaccine
Brand: Menveo
PBAC's latest decision on Meningococcal (groups a, c, w-135 and y) oligosaccharide crm197 conjugate vaccine: Recommended (2023). Considered for Prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135 and Y in adolescents aged 14-19 years as part of school-based or catch-up immunisation programs.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2018
Submissions
3
2018 → 2023
Eligible population
Adolescents aged at least 14 years old but less than 17 years old as part of a school-based program, or aged at least 14 years old but less than 19 years old who did not receive vaccination as part of a school-based program, for prevention of invasive meningococcal disease.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Immunogenicity and safety
Key trials
V59_71 (NCT03652610, Study 205343), V59_78 (NCT03433482, Study 207467)
Comparator
Menveo solution and powder for reconstitution; Nimenrix
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Submission requested the existing nationally negotiated price for MenACWY vaccine with nil net cost to government.
Submission history
Jul 2018: Recommended with restriction · Restricted
Jul 2018: Recommended with restriction · Restricted